Ion channel modulators
AssigneePraxis Precision Medicines, Inc.
InventorsKiran Reddy, Gabriel Martinez Botella, Andrew Mark Griffin, Brian Edward Marron, Carlos Loya
Life of this patent
Estimating the term…
Abstract
The present invention is directed to, in part, fused heteroaryl compounds and compositions useful for preventing and/or treating a disease or condition relating to aberrant function of a voltage-gated, sodium ion channel, for example, abnormal late/persistent sodium current. Methods of treating a disease or condition relating to aberrant function of a sodium ion channel including neurological disorders (e.g., Dravet syndrome, epilepsy), pain, and neuromuscular disorders are also provided herein.
Claims31
1-25. (canceled)
A compound having the Formula II-II:
- or a pharmaceutically acceptable salt thereof, wherein
- R1 is halo;
- R2 is C1-4haloalkyl;
- R3 and R4 are each independently hydrogen or C1-4alkyl;
- or R3 and R4 together with the carbon attached to R3 and R4 form a C3-6carbocyclyl;
- R5 is C1-4alkyl;
- and
- t is 0 or 1.
27-28. (canceled)
31-32. (canceled)
36-37. (canceled)
39-56. (canceled)
A compound of Formula (III-II):
- or a pharmaceutically acceptable salt thereof, wherein:
- R7 is a monocyclic C3-6 cycloalkyl substituted with one or more Ra;
- R5 is selected from the group consisting of halo, C3-6 cycloalkyl, and C1-4alkyl optionally substituted with O—C1-4alkyl or O—C3-6 cycloalkyl;
- R6 is C1-4alkyl or C1-4haloalkyl, wherein the C1-4alkyl or C1-4haloalkyl is each substituted with ORc;
- m is 0, 1, or 2;
- Ra is selected from the group consisting of halo, C1-4alkyl, C1-4haloalkyl, C1-4alkoxy, and C1-4haloalkoxy;
- and
- Rc is C1-4alkyl optionally substituted with C3-6 cycloalkyl or phenyl, or C3-6 cycloalkyl.
58-62. (canceled)
66-68. (canceled)
70-72. (canceled)
A compound selected from the group consisting of:
- or a pharmaceutically acceptable salt thereof.
79-82. (canceled)
84-85. (canceled)
87-100. (canceled)
Dependencies are inferred from the claim text.